About the Project


In December 2019, a novel coronavirus outbreak was documented in Wuhan, Hubei Province, China. Over the first 6 weeks of the new decade, this novel coronavirus, known as SARS-CoV-2, has spread from China to 20 other countries, and WHO characterized Covid-19 as a pandemic. To overcome this pandemic, researchers are actively working to accelerate the development of diagnostics, preventive interventions, therapeutics and vaccines.

This emerging situation requires optimal planning and conduct of research as well as strategies for the appropriate transposition of research into practice.

What is our process?

We are performing a living mapping of ongoing research to monitor in real-time any new evidence that becomes available for treating and preventing Covid-19. In this way, we identify gaps and deficiencies of existing evidence early enough and to help prioritize and optimize future research. Through the process of living systematic reviews, we continuously collect and critically appraise all the available evidence addressing specific clinical outcomes related to Covid-19. Then, using network meta-analysis, we synthesize the available study results and compare simultaneously all possible interventions that could be used in the same clinical setting.

We follow a strict process to identify, appraise and synthesize study results, as detailed in this figure.

For this review, it is crucial that we identify all studies and relevant results as rapidly as possible. Therefore , we are therefore targeting databases from wich clinical trials on Covid-19 can easily be retrieved, and use strategies that maximize specificity.

Information sources are being developed rapidly in the current climate so we will add/modify our evidence sources based on the availability of new eligible resources.

For more information on our process and methods, see our protocol here.

This work received some funding from the Agence Nationale de la Recherche (ANR), the World Health Organization (WHO), Cochrane France, Center of Research in Epidemiology and StatisticS (CRESS), Centre d’Epidémiologie Clinique (GHU Cochin, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (APHP) and Université de Paris) and the Federal Ministry of Health, Germany..